Details for New Drug Application (NDA): 021726
✉ Email this page to a colleague
The generic ingredient in NIRAVAM is alprazolam. There are fifteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the alprazolam profile page.
Summary for 021726
Tradename: | NIRAVAM |
Applicant: | Ucb Inc |
Ingredient: | alprazolam |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021726
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jan 19, 2005 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jan 19, 2005 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jan 19, 2005 | TE: | RLD: | Yes |
Expired US Patents for NDA 021726
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-001 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-002 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-003 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription